INTRODUCTION {#s1}
============

As the second most common malignancy in women worldwide, cervical cancer is the leading cause of cancer death in developing countries that lack organized Pap smear screening \[[@R1]--[@R3]\]. Epidemiologic studies have revealed that the long-term hormone exposure that occurs with high parity and oral contraceptive use is an independent risk factor for invasive cervical cancer (ICC) \[[@R4]--[@R5]\]. In unscreened populations of different countries, the incidence of ICC in women increases with age and plateaus in peri-menopause \[[@R6]\], suggesting a dependence on sex hormones. In the K14-HPV-E6/E7 transgenic mouse model of cervical cancer, an absolute requirement for estrogen and the estrogen receptor (ER) alpha has been proved in the full course of carcinogenesis \[[@R7], [@R8]\]. Cervical neoplasias of differing severities did not appear unless the mice were treated with a physiological level of 17β-estradiol and had a functional *Esr1* gene \[[@R9]\]. Importantly, the administration of a selective estrogen receptor modulator (SERM) led to the regression of the cervical neoplasias \[[@R10]\]. These findings suggest a pivotal role of estrogen and ERα in cervical carcinogenesis. However, evidence from human cervical carcinogenesis is lacking \[[@R11]--[@R13]\].

Aromatase inhibitor (AI) and tamoxifen are the two major antiestrogens that have been prescribed for more than two decades as adjuvant therapies \[[@R14], [@R15]\], and recently as chemoprevention agents for breast cancer \[[@R16]\]. We conducted a nation-wide, population-based study to determine whether antiestrogen use is associated with a lower risk of cervical neoplasia in breast cancer patients.

RESULTS {#s2}
=======

We identified 87,333 eligible breast cancer patients who were registered for the first time in the RCIPD (Figure [1](#F1){ref-type="fig"}). After the exclusion criteria were applied, 42,940 patients were included in this study; 27,743 (64.6%) were antiestrogen users, and 15,197 (35.4%) were nonusers. Among the antiestrogen users, 25,819 (93.1%) had used tamoxifen, 7,551 (27.5%) had used aromatase inhibitor (AI-included users), 478 (1.7%) had used other SERMs, and 5,967 (21.5%) had used multiple antiestrogens during the study period (Figure [1](#F1){ref-type="fig"}). Among the AI-included users, 5,687 (75.3%) had ever used other SERMs and 1,864 (24.7%) used AIs only. The majority (91.1%) of the AI-included users used AI sequentially after discontinuing the use of a SERM. In the AI-included users, the median cDDD (interquartile range, IQR) use of AIs, SERMs, and tamoxifen were 468 (196 to 868), 252 (7 to 681), and 245 (1 to 672) respectively. AIs contributed to 67% (IQR, 31 to 99%) of the total cDDD of antiestrogens use in the AI-included users. The demographic characteristics of the groups are shown in Table [1](#T1){ref-type="table"}. The AI-included users were generally older than the tamoxifen-only users and nonusers. The numbers of subjects identified across the years of the study were similar among the three groups. Greater proportions of nonusers (70.5%) and AI-included users (70.6%) had received chemotherapy compared to the tamoxifen-only users (54.1%). An average of 93.1% and roughly equal proportions of patients in each group had completed their primary therapy within 270 days after the diagnosis of breast cancer. The AI-included users had a slightly longer follow-up duration (median 4.11 years, IQR 2.29 to 5.00) than the tamoxifen-only users (median 3.75 years, IQR 1.82 to 5.00) and the nonusers (median 3.52 years, IQR 1.65 to 5.00). The mortality rate was higher in the nonusers and AI-included users (both 10.7%) than in the tamoxifen-only users (2.9%). A high proportion of antiestrogen users (81.4% in AI-included users and 74.1% in tamoxifen-only users) adhered to the medication for more than half of the cDDD in study period (days).

![Selection of study population and status of antiestrogen use](oncotarget-08-29361-g001){#F1}

###### Demographics and clinical characteristics of the breast cancer cohort with 5 year follow-up

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                                                All patients with breast cancer\   Nonuser\          AI-included\       Tamoxifen only user\   *P*-value                           
                                                                                (*N*=42940)                        (*N*=15197,\      user\              (*N*=19875,\                                               
                                                                                                                   35.7%)            (*N*=7551,\        46.6%)                                                     
                                                                                                                                     17.7%)                                                                        
  ----------------------------------------------------------------------------- ---------------------------------- ----------------- ------------------ ---------------------- ----------- ------- ------- ------- -----------
  SERM use                                                                      25879                              60.3              ---                ---                    5687        75.3    19875   100.0   ---

   Tamoxifen                                                                    25819                              60.1              ---                ---                    5664        75.0    19875   100.0   

   Raloxifen                                                                    157                                0.4               ---                ---                    62          0.8     0       0.0     

   Toremifen                                                                    250                                0.6               ---                ---                    96          1.3     0       0.0     

   Clomifene                                                                    73                                 0.2               ---                ---                    4           0.1     0       0.0     

  AI-included use^a^                                                            7551                               17.6              ---                ---                    7551        100.0   0       0.0     ---

  Age at breast cancer diagnosis (years)                                                                                                                                                                           \< 0.0001

   18-39                                                                        5549                               12.9              2116               13.9                   314         4.2     3045    15.3    

   40-49                                                                        13929                              32.4              4260               28.0                   1750        23.2    7820    39.4    

   50-59                                                                        12490                              29.1              5088               33.5                   2787        36.9    4562    23.0    

   ≥ 60                                                                         10972                              25.6              3733               24.6                   2700        35.8    4448    22.4    

  Year of breast cancer diagnosis                                                                                                                                                                                  \< 0.0001

   2002                                                                         2497                               5.8               870                5.7                    425         5.6     1162    5.9     

   2003                                                                         2555                               6.0               946                6.2                    461         6.1     1107    5.6     

   2004                                                                         2991                               7.0               1068               7.0                    600         8.0     1293    6.5     

   2005                                                                         3662                               8.5               1299               8.6                    724         9.6     1605    8.1     

   2006                                                                         3734                               8.7               1283               8.4                    781         10.3    1635    8.2     

   2007                                                                         4176                               9.7               1420               9.3                    888         11.8    1839    9.3     

   2008                                                                         4718                               11.0              1616               10.6                   928         12.3    2140    10.8    

   2009                                                                         5126                               11.9              1824               12.0                   932         12.3    2340    11.8    

   2010                                                                         5601                               13.0              2012               13.2                   877         11.6    2691    13.5    

   2011                                                                         5747                               13.4              2030               13.4                   765         10.1    2935    14.8    

   2012                                                                         2133                               5.0               829                5.5                    170         2.3     1128    5.7     

  Chemotherapy for breast Cancer                                                26927                              62.7              10718              70.5                   5332        70.6    10742   54.1    \< 0.0001

  Breast cancer diagnosis to follow up start (day), median (IQR)                141 (21 to197)                     143 (18 to 196)   160 (35 to 213)    130 (20 to 190)        \< 0.0001                           

   0-90                                                                         16153                              37.6              5034               33.1                   2324        30.8    8616    43.4    

   91-180                                                                       13084                              30.5              5360               35.3                   2188        29.0    5467    27.5    

   181-270                                                                      10749                              25.0              3209               21.1                   2495        33.0    4988    25.1    

   271-360                                                                      2954                               6.9               1594               10.5                   544         7.2     804     4.1     

  Follow up period (year), median (IQR)                                         3.76\                              3.52\             4.11\              3.75\                  \< 0.0001                           
                                                                                (1.83 to 5.00)                     (1.65 to 5.00)    (2.29 to 5.00)     (1.82 to 5.00)                                             

  Mortality                                                                     3040                               7.1               1627               10.7                   806         10.7    583     2.9     \< 0.0001

  Antiestrogen adherence^b^                                                                                                                                                                                        ---

  Nonuser                                                                       15197                              35.4              15197              100.0                  ---         ---     ---     ---     

   \<0.5                                                                        2038                               4.8               ---                ---                    1405        18.6    5145    25.9    

   0.5-0.7                                                                      4625                               10.8              ---                ---                    1276        16.9    3227    16.2    

   0.7-0.9                                                                      4555                               10.6              ---                ---                    1493        19.8    3459    17.4    

   ≥ 0.9                                                                        5012                               11.7              ---                ---                    3377        44.7    8044    40.5    

  Ever Pap smear                                                                29213                              68.0              8895               58.5                   5271        69.8    14807   74.5    \< 0.0001

  Pap smear every two years^c^                                                  13389                              31.2              3577               23.5                   2174        28.8    7548    38.0    \< 0.0001

  Pap smear density^d^ (times/year),\                                           0.40\                              0.22\             0.40\              0.55\                  \< 0.0001                           
  median (IQR)                                                                  (0.00 to 0.78)                     (0 to 0.62)       (0 to 0.76)        (0 to 0.87)                                                

  Antiestrogen accumulated dose (cumulative defined daily dose), median (IQR)                                                                                                  ---                                 

   Antiestrogen                                                                 ---                                ---               949\               ---                                                        
                                                                                                                                     (532 to 1490)                                                                 

   SERM                                                                                                                              252\               ---                                                        
                                                                                                                                     (7 to 681)                                                                    

   Tamoxifen                                                                    ---                                ---               245\               742\                                                       
                                                                                                                                     (1 to 672)         (382 to 1311)                                              

   AI^a^                                                                        ---                                ---               468 (196 to 868)   ---                                                        

  AI cDDD/Antiestrogen cDDD (%), median (IQR)                                   ---                                ---               67 (31 to 99)      ---                    ---                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SERM: selective estrogen receptor modulator, AI: aromatase inhibitor; IQR: interquartile ranges, cDDD: cumulative defined daily dose

^a^AI: Exemestane or Letrozole or Anastrozole or Aminoglutethimide

^b^Antiestrogen adherence = cumulative defined daily dose/period of follow-up (day)

^c^Pap smear every two years: patients who had Pap smear at least once in every two years during follow-up

^d^Pap smear density = number of Pap smear/follow-up year

After adjusting for age, Pap smear density and chemotherapy (Table [3](#T3){ref-type="table"}), the AI-included users exhibited a lower risk of low-grade cervical dysplasia than the nonusers \[adjusted hazard ratio (HR) = 0.42, 95% confidential interval (CI), 0.29 to 0.64, *P* \< 0.0001\] in the five-year follow-up analysis. The hazard ratio was more prominent in the patients who had received Pap smears at least once every two years (HR = 0.32, 95% CI, 0.20 to 0.50, *P* \< 0.0001), in the younger (18 to 49 years) group (HR = 0.23, 95% CI, 0.1 to 0.5, *P =* 0.0002), and also in the older (≥50 years) group (HR = 0.41, 95% CI, 0.23 to 0.72, *P* = 0.0019).

Similar results were found for high-grade dysplasia in AI-included users in the 10-year follow up (HR = 0.60, 95% CI, 0.39 to 0.93, *P* = 0.0231). A lower risk was also noted in the older (≥50 years) group (HR = 0.44, 95% CI, 0.24 to 0.79, *P* = 0.0058) in subgroup analysis. This phenomenon was also more prominent in the older (≥50 years) patient who received regular Pap smears at least once every two years in both the 5-year and 10-year follow-up analyses (HR = 0.30, 95% CI, 0.12 to 0.74, *P* = 0.0092 and HR = 0.34, 95% CI, 0.14 to 0.80, *P* = 0.014, respectively) (Table [3](#T3){ref-type="table"}). Due to the limited event number, there was no association of antiestrogen use and the incidence of ICC in the 10-year follow-up (Table [2](#T2){ref-type="table"}). The use of tamoxifen only revealed a marginal lower risk of cervical neoplasia. A lower risk of low-grade cervical dysplasia was noted in the young age (18 to 49 years) group that had undergone Pap smears at least once every two years (HR = 0.67, 95% CI, 0.48 to 0.93, *P* = 0.0167) (Table [3](#T3){ref-type="table"}).

###### Association between antiestrogens use and incidence of cervical neoplasia in the breast cancer cohort

                                    5 year follow-up   10 year follow-up                                                                                     
  --------------------------------- ------------------ ------------------- --------- -------- -------- --------- -------- -------- --------- ------- ------- -------
  No. of patients                   15136              7516                19761     15076    7510     19660     14893    8084     19018     14843   8064    18935
  Patients with event               113                33                  200       53       27       99        63       30       103       13      10      20
  Person-years                      49154              26953               66633     49095    26942    66415     60919    38091    79764     60780   38025   79610
  Incidence per 10^5^person-years   230                122                 300       108      100      149       103      79       129       21      26      25
  95% CI                            191-276            86.8-172            261-344   82-141   68-146   122-181   80-132   55-112   106-156   12-36   14-48   16-38

HR: hazard ratio;

^a^Model adjusted for age, Pap smear density and chemotherapy

###### Subgroup analysis of Cox\'s regression model for the association between antiestrogens use and cervical neoplasia

  Modela                             5 year follow-up   10 year follow-up                                                                                     
  -------------------------- ------- ------------------ ------------------- ----------- ---------- ----- ------ ----------- -------- ----- ------ ----------- --------
  All study population       42623   346                                                           179                               196                      
  Main model                                                                                                                                                  
   Nonuser                   15197   113                1.0                                        53    1.0                         63    1.0                
   AI-included               7551    33                 0.42                0.29-0.64   \<0.0001   27    0.73   0.45-1.16   0.1780   30    0.60   0.39-0.93   0.0231
   Tamoxifen only            19875   200                0.87                0.69-1.11   0.2661     99    0.94   0.67-1.33   0.7246   103   0.87   0.63-1.2    0.3943
  Age, years                                                                                                                                                  
  18-49                                                                                                                                                       
   Nonuser                   6376    62                 1.0                                        22    1.0                         25    1.0                
   AI-included               2064    13                 0.40                0.22-0.74   0.0031     13    1.19   0.59-2.38   0.6315   14    0.93   0.48-1.81   0.8298
   Tamoxifen only            10865   119                0.75                0.55-1.03   0.0717     64    1.22   0.74-1.99   0.4374   67    1.15   0.72-1.83   0.5682
  ≥50                                                                                                                                                         
   Nonuser                   8821    51                 1.0                                        31    1.0                         38    1.0                
   AI-included               5487    20                 0.45                0.27-0.76   0.0028     14    0.51   0.27-0.96   0.0359   16    0.44   0.24-0.79   0.0058
   Tamoxifen only            9010    81                 1.04                0.73-1.49   0.8319     35    0.74   0.45-1.21   0.2305   36    0.67   0.42-1.07   0.0922
  Pap smear every two year   13299   296                                                           128                               135                      
  Main model                                                                                                                                                  
   Nonuser                   3541    95                 1.0                                        34    1.0                         36    1.0                
   AI-included               2157    24                 0.32                0.20-0.50   \<0.0001   12    0.43   0.22-0.83   0.0122   15    0.49   0.27-0.90   0.0212
   Tamoxifen only            7455    177                0.78                0.61-1.01   0.0565     82    1.01   0.67-1.52   0.9556   84    1.01   0.68-1.50   0.9690
  Age, years                                                                                                                                                  
  18-49                                                                                                                                                       
   Nonuser                   1694    53                 1.0                                        14    1.0                         16    1.0                
   AI-included               702     7                  0.23                0.10-0.50   0.0002     6     0.73   0.28-1.93   0.5293   8     0.79   0.34-1.87   0.5952
   Tamoxifen only            4680    108                0.67                0.48-0.93   0.0167     50    1.17   0.65-2.12   0.6042   51    1.07   0.61-1.89   0.8143
  ≥50                                                                                                                                                         
   Nonuser                   1883    42                 1.0                                        20    1.0                         20    1.0                
   AI-included               1472    17                 0.41                0.23-0.72   0.0019     6     0.30   0.12-0.74   0.0092   7     0.34   0.14-0.80   0.0140
   Tamoxifen only            2868    69                 0.95                0.64-1.41   0.8034     32    0.90   0.51-1.59   0.7124   33    0.97   0.55-1.73   0.9253

The cumulative incidences of low-and high-grade cervical dysplasia are shown in the Kaplan-Meier analysis in Figure [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}. The AI-included users exhibited lower cumulative incidences of low- (log-rank test, *P* \< 0.0001) and high-grade cervical dysplasia (log-rank test, *P* \< 0.0029) compared to the nonuser and tamoxifen-only user groups.

![**Kaplan-Meier analysis for the association between antiestrogens use and A. low-grade dysplasia, B. high-grade dysplasia, for patients with Pap smear at least once every two year in 5 years follow-up analysis**.](oncotarget-08-29361-g002){#F2}

DISCUSSION {#s3}
==========

To our knowledge, this is the first population-based study to demonstrate that use of antiestrogen, especially the AI-included antiestrogen use, is associated with a lower incidence of cervical neoplasia. The protection against low grade cervical dysplasia was evident in a manner of no correlation to the age of subjects, whereas for high grade cervical dysplasia it was observed only in subjects ≥50 years old (Table [3](#T3){ref-type="table"}, heterogeneity tests showed no different between subjects at 18-49 and ≥50 years old, *P* = 0.00541 and *P* = 0.0849 in 5- and 10-years analyses respectively in the main model; *P* = 0.0969 and *P* = 0.2358 in 5- and 10-years analyses in the regular pap screening subgroup, respectively, data not shown). This is in accordance with the natural histories of cervical tumorigenesis which displays an early onset of low grade dysplasia after HPV infection and a 2 to 5 years period to progress to high grade dysplasia which may last for more than one decade \[[@R17]\]. In accordance with the primary role of Pap screening in the detection of pre-invasive cervical lesions, the protective effect was even more obvious in the subjects who had received regular Pap smears. The sensitivity and specificity Pap smear for the detection of high-grade dysplasia or more severe cervical neoplasia in Taiwan is 81.9% and 98.6% respectively \[[@R18]\]. Meanwhile, the nation-wide 3-year screening rate increased from 14.5% in 1995 to 75.9% in 2014 \[[@R19]\]. In this population with breast cancer, an even higher screening rate was noted. A higher incidence of cervical neoplasias could be expected in these two user groups, but instead, we observed lower incidences. Thus, the hazard ratios for subgroup of "Pap smear at least once every two years" was more closely reflected the protective effects of antiestrogens on the occurrence of cervical neoplasias.

Tamoxifen use exhibited a marginal protection effect on cervical neoplasia, except in the subgroup of young patients with regular Pap smears, a lower risk of low-grade cervical dysplasia was noted (Table [3](#T3){ref-type="table"}). This finding might be explained by the fact that tamoxifen acts as an ER agonist rather than antagonist in the uterus \[[@R20], [@R21]\]. The long-term use of tamoxifen in breast cancer patients actually increases the risks of endometrial and uterine stromal cancers \[[@R22]\]. However, studies of breast cancer patients who used tamoxifen did not reveal an increase in the incidence of abnormal cervical cytology \[[@R23]\]. Meanwhile, a phase 2 clinical trial reported a modest therapeutic effect of tamoxifen in recurrent non-squamous cell carcinomas of the cervix \[[@R13]\].

Although 78.7% of the AI-included users had ever used tamoxifen (Figure [1](#F1){ref-type="fig"}), the cDDD for tamoxifen was only 25.8% of the total cDDD antiestrogen in this group. Given that tamoxifen was neutral or only modestly effective in reducing the risk of cervical neoplasia, the protective effect of AI-included antiestrogen use can be attributed by the AIs. This result resembles the case of antiestrogen use in ER and/or progesterone receptor (PR)-positive breast cancer in which AI is more effective than tamoxifen in preventing recurrence of breast cancer \[[@R24]\]. Due to the limited number of cases with pure AI use (only 1,864 or 6.7% of all of the antiestrogens users), this study was not able to provide direct evidence regarding pure AI in the protection against cervical neoplasia.

This study has several strengths. First, this naturally occurring and passively followed cohort was devoid of selection or recall bias. Second, the use of antiestrogens in breast cancer patients was based on the expression of the ER and/or PR in the tumors, which is unrelated to the systemic health or the occurrence of cervical neoplasia. Third, because antiestrogens are essential for preventing the recurrence of breast cancer, drug adherence of the antiestrogen users was extraordinarily strong; 81.4% of AI-included users, and 74.1% of tamoxifen-only users exhibited adherences above half of the cDDD in the study period. Fourth, the main tool for outcome detections, the Pap smear, is sufficiently sensitive and specific and was widely applied in the study population. Finally, the 10-year follow-up period was sufficient to identify most of the occurrences of non-invasive cervical neoplasias. Due to the transient nature of low-grade cervical dysplasias and the fact that tamoxifen is typically used for five years after the primary therapy for breast cancer, we purposely set the analysis period to 5 years for low-grade dysplasia. In the analysis of high-grade cervical dysplasia, of which *in situ* carcinomas comprise a major portion, and the natural history is as long as 10 years or more, a longer follow-up is mandatory. Indeed, in the 10-year follow up, the AI-included users of postmenopausal ages exhibited a low risk (HR = 0.34, 95% CI, 0.14 to 0.80, *P* = 0.014) for high-grade cervical dysplasias. Additionally, the lack of ICC in the study population may due to relatively adequate screening that prevent the development of cancer.

There are also limitations of this study. As mentioned previously, the effect of AI was analyzed in the larger group of AI-included users and not in a group of pure AI users. Information regarding other confounders of cervical cancer, such as HPV infection status \[[@R2]\] \[[@R3]\], smoking \[[@R25]\], number of sexual partner \[[@R26]\] and sex hormone exposure (e.g. menopause, parity, and oral contraceptives pill use) was lacking. The smoking rate among Taiwanese women is as low as 4.3% \[[@R27]\]. Oral contraceptive use is also not popular in Taiwan. Therefore, the effect from these two factors may be minimal. Regarding to the major confounder of HPV infection, discrepant risks or prevalence of HPV infection may not present between groups, although the tamoxifen-only users, who exhibited a lower mortality rate, may have been more likely to maintain sexual activity and more prone to HPV infection.

In summary, this study demonstrated that antiestrogen use especially AI is associated with a reduction in cervical dysplasia.

MATERIALS AND METHODS {#s4}
=====================

Study population and study design {#s4_1}
---------------------------------

The Taiwan National Health Insurance (NHI) database consists of health information from 23 million inhabitants since 1997. The database includes comprehensive disease diagnoses, hospital admissions, outpatient visits and prescription medications. Data for this study were obtained from the Registry for Catastrophic Illness Patient Database (RCIPD), which is a subset of the Taiwan NHI database that contains the complete medical records of all cancer patients. Due to the Registry of Catastrophic Illness, cancer patients receive medical care nearly free of charge while under NHI coverage. This database has been used extensively for epidemiologic research, and the information about diagnoses, prescription medications and hospitalizations is of reliable quality \[[@R28]\].

In this study, newly diagnosed breast cancer patients who were registered with the RCIPD from January 1, 2002 to December 31, 2012 were identified using the International Classification of Diseases, 9th Revision (ICD-9), codes 174.0 to174.9. Figure [1](#F1){ref-type="fig"} shows the study design, exclusion criteria and the status of antiestrogen use in the study population. We excluded subjects who were male or younger than 18 years old, those with histories of cervical dysplasia, cervical carcinoma *in situ* (CIS), ICC and other cancers, those who had undergone hysterectomy, bilateral oophorectomy, cervical amputation, or cervical conization before or on the date of breast cancer diagnosis. We also excluded those with lymph node or distant metastases and subjects who did not receive standard primary therapy (an operation and/or chemotherapy) for breast cancer. To standardize the follow up protocol of the antiestrogen users and nonusers, those who had used antiestrogen before the end of standard primary therapy or one year after the diagnosis of breast cancer were excluded. The defined daily dose (DDD) advocated by the WHO was used to standardize the comparisons of drug usage between the different drugs, and the cumulative DDD (cDDD) of the antiestrogen users was calculated. Those with antiestrogen use that was less than 90 cDDD and whose follow-up periods were less than three months were also excluded.

The antiestrogens covered by the NHI during the study period for breast cancer adjuvant therapy included four SERMs (tamoxifen, raloxifen, toremifene and clomifene) and four AIs (anastrozole, letrozole, aminoglutethimide, and exemestane). To demonstrate the compliance with and consistency of the antiestrogen use, adherence was calculated by dividing the cDDD by duration of the follow-up period (days). To compare the effect of the different antiestrogens on cervical neoplasia, the patients were divided into three groups: nonusers, antiestrogen users who had ever used aromatase inhibitors, and antiestrogen users who had used tamoxifen only.

The follow-up scheme is shown in supplement ([Figure S1](#SD1){ref-type="supplementary-material"}). All breast cancer patients with or without antiestrogen use were followed after completion of the standard primary therapy for breast cancer. The follow up was initiated when the antiestrogen users began to use antiestrogen and when the nonusers had received the last primary therapy. All patients were followed until the occurrence of the most severe form of cervical neoplasias, the end of the study or death. Thus, if patient\'s medical records contained high-grade dysplasia and ICC during follow up period, only ICC was counted. The identification of ICC was based on a new registration of ICC in the RCIPD or by the diagnosis of ICC during hospitalization using the ICD-9 codes 180.0 to180.9. High-grade cervical dysplasia was identified by the diagnostic codes for cervical CIS (ICD-9 code 233.1) and cervical dysplasia (ICD-9 code 622.1) accompanied by the therapeutic procedure of cervical conization. Low-grade cervical dysplasia of the cervix was identified using the ICD-9 code 622.1 accompanied by procedures for cervical biopsy and/or endocervical curettage.

We explored several risk factors including age \[[@R6]\], Pap smear density \[[@R29]\], and chemotherapy treatment \[[@R30]\] that might have interfered with the association between antiestrogen use and the risk of cervical neoplasia. Pap smear density was calculated as the number of Pap smears divided by the number of follow-up person-years. This study was approved by the Research Ethics Committee of the medical center Hualien Tzu Chi Hospital, Hualien, Taiwan (IRB101-98).

Statistical analysis {#s4_2}
--------------------

Based on a Cox proportional hazards model, the hazard ratios (HRs) and accompanying 95% confidence intervals (CIs) were computed with adjusting for age at the time of breast cancer diagnosis, Pap smear density and chemotherapy. Since death is a competing risk for loss to follow-up, we also did a competing risk analysis by Fine and Gray method \[[@R31]\]. The consistencies and differences in the risk of cervical neoplasia were evaluated by conducting subgroup analyses based on age and Pap smear. To test whether excluding subjects whose follow-up periods were less than three months would cause selection bias, sensitivity analyses of including all the subjects or excluding the subjects with different follow-up period were conducted ([Table S1](#SD1){ref-type="supplementary-material"}). The cumulative incidence of cervical neoplasia was plotted using the Kaplan-Meier method, and the differences between the curves were tested with the log-rank test. The occurrence of cervical dysplasia is always identified by Pap screening \[[@R18]\], therefore, the cumulative incidence of cervical dysplasia was analyzed in the subgroup of patients who underwent Pap smears at least once every two years. The statistical analyses were performed using SAS, version 9.4 (SAS Institute, Inc., Cary, NC) and all tests were two-sided.

SUPPLEMENTARY MATERIALS FIGURES AND TABLE {#s5}
=========================================
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